These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38330830)

  • 21. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
    Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
    Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of real-time magnetic resonance imaging-transrectal ultrasound fusion image-guided transperineal target biopsy with needle tracking with a mechanical position-encoded stepper in detecting significant prostate cancer in biopsy-naïve men.
    Shoji S; Hiraiwa S; Ogawa T; Kawakami M; Nakano M; Hashida K; Sato Y; Hasebe T; Uchida T; Tajiri T
    Int J Urol; 2017 Apr; 24(4):288-294. PubMed ID: 28222486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of disparity between targeted and in-zone systematic cores during transrectal MR/US-fusion prostate biopsy.
    Kuhlmann PK; Chen M; Luu M; Naser-Tavakolian A; Kim HL; Saouaf R; Daskivich TJ
    Urol Oncol; 2022 Apr; 40(4):162.e1-162.e7. PubMed ID: 35067431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of 3T multiparametric prostate MRI using prostate imaging reporting and data system (PIRADS) version 2 with biopsy as reference standard.
    Mathur S; O'Malley ME; Ghai S; Jhaveri K; Sreeharsha B; Margolis M; Zhong L; Maan H; Toi A
    Abdom Radiol (NY); 2019 Jan; 44(1):252-258. PubMed ID: 30032385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
    Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
    J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
    Seyfried N; Mahran A; Panda A; Obmann VC; Buzzy CA; Jiang Y; Wright KL; Nakamoto DA; Patel IJ; Conroy B; Ponsky L; Gulani V
    AJR Am J Roentgenol; 2021 Oct; 217(4):908-918. PubMed ID: 33336582
    [No Abstract]   [Full Text] [Related]  

  • 30. Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy.
    Vėželis A; Platkevičius G; Kinčius M; Gumbys L; Naruševičiūtė I; Briedienė R; Petroška D; Ulys A; Jankevičius F
    Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435132
    [No Abstract]   [Full Text] [Related]  

  • 31. MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men.
    Tan TW; Png KS; Lee CH; Yuwono A; Yeow Y; Chong KT; Lee YM; Tan CH; Tan YK
    J Endourol; 2017 Nov; 31(11):1111-1116. PubMed ID: 28797178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Brisbane WG; Priester AM; Ballon J; Kwan L; Delfin MK; Felker ER; Sisk AE; Hu JC; Marks LS
    Eur Urol; 2022 Sep; 82(3):303-310. PubMed ID: 35115177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    Song G; Ruan M; Wang H; Fan Y; He Q; Lin Z; Li X; Li P; Wang X; He Z; Zhou L
    J Urol; 2020 Dec; 204(6):1202-1208. PubMed ID: 32716686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting.
    Schlenker B; Apfelbeck M; Armbruster M; Chaloupka M; Stief CG; Clevert DA
    Clin Hemorheol Microcirc; 2019; 71(2):165-170. PubMed ID: 30562897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
    Günzel K; Magheli A; Busch J; Baco E; Cash H; Heinrich S; Edler D; Schostak M; Borgmann H; Schlegel J; Hinz S
    Int Urol Nephrol; 2022 Oct; 54(10):2477-2483. PubMed ID: 35877030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection.
    Ber Y; Segal N; Tamir S; Benjaminov O; Yakimov M; Sela S; Halstauch D; Baniel J; Kedar D; Margel D
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):449-456. PubMed ID: 31953483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
    Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
    Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
    Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of mapping-targeted biopsies on the index lesion in transperineal prostate biopsies.
    Paesano N; Catalá V; Tcholakian L; Alomar X; Barranco M; Trilla E; Morote J
    Int Braz J Urol; 2024; 50(3):296-308. PubMed ID: 38446907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.